<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:creativeCommons="http://backend.userland.com/creativeCommonsRssModule" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Nature Precedings - Bernd Kastenholz</title>
    <link>http://precedings.nature.com/users/3c074c0aa34d0fcb9b5e77586aabd41e/</link>
    <description>Documents posted by Bernd Kastenholz</description>
    <dc:publisher>Nature Publishing Group</dc:publisher>
    <dc:language>en</dc:language>
    <prism:publicationName>Nature Precedings</prism:publicationName>
    <image>
      <title>Nature Precedings</title>
      <url>http://precedings.nature.com/images/header_logo.gif</url>
      <link>http://precedings.nature.com</link>
    </image>
    <atom:link type="application/rss+xml" rel="self" href="http://precedings.nature.com/users/3c074c0aa34d0fcb9b5e77586aabd41e/feed"/>
    <item>
      <title>Herbal Drugs in Mirror of Alzheimer&#8217;s Disease</title>
      <link>http://dx.doi.org/10.1038/npre.2009.3334.1</link>
      <description>Commercially available Ginkgo biloba leaf extracts may lack specificity as to the binding of copper and zinc ions in human cells. This might be the reason why Ginkgo extracts have no predictable and clinically significant benefit for people with dementia or cognitive impairment. A novel generation of herbal drugs is proposed as antioxidant and metal chelator in the treatment of Alzheimer&amp;#8217;s disease.</description>
      <guid>http://dx.doi.org/10.1038/npre.2009.3334.1</guid>
      <pubDate>Thu, 11 Jun 2009 19:26:49 UTC</pubDate>
      <dc:title>Herbal Drugs in Mirror of Alzheimer&#8217;s Disease</dc:title>
      <dc:identifier>doi:10.1038/npre.2009.3334.1</dc:identifier>
      <dc:date>2009-06-11</dc:date>
      <dc:creator>Bernd Kastenholz</dc:creator>
      <prism:publicationName>Nature Precedings</prism:publicationName>
      <prism:publicationDate>2009-06-11T19:26:49Z</prism:publicationDate>
      <prism:category>Manuscript</prism:category>
      <prism:section>Biotechnology</prism:section>
      <prism:section>Neuroscience</prism:section>
      <prism:section>Pharmacology</prism:section>
      <prism:section>Plant Biology</prism:section>
      <media:thumbnail url="http://precedings.nature.com/documents/3334/version/1/files/npre20093334-1.pdf.thumb.png"/>
      <creativeCommons:license>http://creativecommons.org/licenses/by/3.0/</creativeCommons:license>
    </item>
    <item>
      <title>Phytochemical Approach and Bioanalytical Strategy to Develop Chaperone-Based Medications</title>
      <link>http://precedings.nature.com/documents/1431/version/2</link>
      <description>Currently, no pharmaceuticals for the etiological treatment of degenerative protein-misfolding diseases (e.g., ALS, Alzheimer&#8217;s or prion diseases) are commercially available. Therefore, in this technical note theoretical considerations and practical approaches concerning the development of chaperone-based medications from medicinal plants (e.g., Ginkgo biloba) are reviewed and discussed in detail. Phytochaperones and other agents isolated from medicinal plants are proposed to serve as the general basis of drug development in protein-misfolding diseases.</description>
      <guid>http://precedings.nature.com/documents/1431/version/2</guid>
      <pubDate>Wed, 09 Apr 2008 13:56:55 UTC</pubDate>
      <dc:title>Phytochemical Approach and Bioanalytical Strategy to Develop Chaperone-Based Medications</dc:title>
      <dc:identifier>hdl:10101/npre.2008.1431.2</dc:identifier>
      <dc:date>2008-04-09</dc:date>
      <dc:creator>Bernd Kastenholz</dc:creator>
      <prism:publicationName>Nature Precedings</prism:publicationName>
      <prism:publicationDate>2008-04-09T13:56:55Z</prism:publicationDate>
      <prism:category>Manuscript</prism:category>
      <prism:section>Chemistry</prism:section>
      <prism:section>Pharmacology</prism:section>
      <prism:section>Plant Biology</prism:section>
      <media:thumbnail url="http://precedings.nature.com/documents/1431/version/2/files/npre20081431-2.pdf.thumb.png"/>
      <creativeCommons:license>http://creativecommons.org/licenses/by/3.0/</creativeCommons:license>
    </item>
    <item>
      <title>Quantitative Preparative Native Continuous Polyacrylamide Gel Electrophoresis (QPNC-PAGE)</title>
      <link>http://dx.doi.org/10.1038/npre.2008.1782.1</link>
      <description>QPNC-PAGE, or quantitative preparative native continuous polyacrylamide gel electrophoresis, is a high-resolution technique applied in biochemistry and bioinorganic chemistry to separate proteins by isoelectric point. This variant of gel electrophoresis is used by biologists to isolate active or native metalloproteins in biological samples and to resolve properly and improperly folded metal cofactor-containing proteins in complex protein mixtures.</description>
      <guid>http://dx.doi.org/10.1038/npre.2008.1782.1</guid>
      <pubDate>Tue, 08 Apr 2008 20:04:21 UTC</pubDate>
      <dc:title>Quantitative Preparative Native Continuous Polyacrylamide Gel Electrophoresis (QPNC-PAGE)</dc:title>
      <dc:identifier>doi:10.1038/npre.2008.1782.1</dc:identifier>
      <dc:date>2008-04-08</dc:date>
      <dc:creator>Bernd Kastenholz</dc:creator>
      <prism:publicationName>Nature Precedings</prism:publicationName>
      <prism:publicationDate>2008-04-08T20:04:21Z</prism:publicationDate>
      <prism:category>Poster</prism:category>
      <prism:section>Chemistry</prism:section>
      <media:thumbnail url="http://precedings.nature.com/documents/1782/version/1/files/npre20081782-1.pdf.thumb.png"/>
      <creativeCommons:license>http://creativecommons.org/licenses/by/3.0/</creativeCommons:license>
    </item>
  </channel>
</rss>
